8 results found.

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.
fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocyt Clinical Trial using alemtuzumab; rituximab; PGG beta-glucan; flow cytometry; laboratory biomarker analysis; DNA analysis; fluorescence in situ hybridization; polymerase chain reaction; polymorphism analysis; mutation analysis

Mayo Clinic - Recruiting 18 years or older.
- Early Treatment of High Risk Chronic Lymphocytic Leukemia With Alemtuzumab, Rituximab, and PGG Beta-Glucan: A Phase I/II Trial.
alemtuzumab; rituximab; PGG beta-glucan; flow cytometry; laboratory biomarker analysis; DNA analysis; fluorescence in situ hybridization; polymerase chain reaction; polymorphism analysis; mutation analysis

Chronic Lymphocytic Leukemia Clinical Trial using Ofatumumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients With Chronic Lymphocytic Leukemia (CLL).
Ofatumumab

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocyti Clinical Trial using ibrutinib; rituximab; bendamustine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 65 years or older.
- A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (ò 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL).
ibrutinib; rituximab; bendamustine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymph Clinical Trial using bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years to 70 years.
- A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Sta Clinical Trial using MOR00208; lenalidomide; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years to 80 years.
- A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)Prolymphocytic Leukemia (PLL) or Patients With Untreated CLL/SLL/PLL.
MOR00208; lenalidomide; Correlative Studies

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocyti Clinical Trial using alemtuzumab; ofatumumab; biopsy

Northwestern University - Recruiting 18 years or older.
- A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia.
alemtuzumab; ofatumumab; biopsy

Chronic Lymphocytic Leukemia Stage A(0), Chronic Lymphocytic Leuk Clinical Trial

Gruppo Italiano Studio Linfomi - Recruiting 18 years to 80 years.
- Prospective Collection of Biological Data of Prognostic Relevance in Patients.